{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:40:12Z","timestamp":1793878812876,"version":"4.7.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Human melanocytic nevi (moles) result from a brief period of clonal expansion of melanocytes. As a cellular defensive mechanism against oncogene-induced hyperplasia, nevus-resident melanocytes enter a senescent state of stable cell cycle arrest. Senescent melanocytes can persist for months in mice and years in humans with a risk to escape the senescent state and progress to melanoma. The mechanisms providing prolonged survival of senescent melanocytes remain poorly understood. Here, we show that senescent melanocytes in culture and in nevi express high level of the anti-apoptotic BCL-2 family member BCL-W but remain insensitive to the pan-BCL-2 inhibitor ABT-263. We demonstrate that resistance to ABT-263 is driven by mTOR-mediated enhanced translation of another anti-apoptotic member, MCL-1. Strikingly, the combination of ABT-263 and MCL-1 inhibitors results in synthetic lethality to senescent melanocytes, and its topical application sufficient to eliminate nevi in male mice. These data highlight the important role of redundant anti-apoptotic mechanisms for the survival advantage of senescent melanocytes, and the proof-of-concept for a non-invasive combination therapy for nevi removal.<\/jats:p>","DOI":"10.1038\/s41467-022-35657-9","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T13:11:38Z","timestamp":1671801098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression"],"prefix":"10.1038","volume":"13","author":[{"given":"Jaskaren","family":"Kohli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1758-747X","authenticated-orcid":false,"given":"Chen","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5719-6345","authenticated-orcid":false,"given":"Eleni","family":"Fitsiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Doepner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6144-6194","authenticated-orcid":false,"given":"Simone M.","family":"Brandenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0738-2254","authenticated-orcid":false,"given":"William J.","family":"Faller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8482-1284","authenticated-orcid":false,"given":"Todd W.","family":"Ridky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8429-4813","authenticated-orcid":false,"given":"Marco","family":"Demaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"35657_CR1","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jaad.2017.06.149","volume":"77","author":"R Pampena","year":"2017","unstructured":"Pampena, R. et al. A meta-analysis of nevus-associated melanoma: prevalence and practical implications. J. Am. Acad. Dermatol. 77, 938\u2013945.e4 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"35657_CR2","doi-asserted-by":"publisher","first-page":"515.e1","DOI":"10.1016\/j.jaad.2012.06.022","volume":"67","author":"OA Ibrahimi","year":"2012","unstructured":"Ibrahimi, O. A., Alikhan, A. & Eisen, D. B. Congenital melanocytic nevi: where are we now?: Part II. treatment options and approach to treatment. J. Am. Acad. Dermatol. 67, 515.e1\u2013515.e13 (2012).","journal-title":"J. Am. Acad. Dermatol."},{"key":"35657_CR3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1046\/j.0022-202X.2004.22225.x","volume":"122","author":"R Kumar","year":"2004","unstructured":"Kumar, R., Angelini, S., Snellman, E. & Hemminki, K. BRAF mutations are common somatic events in melanocytic nevi. J. Invest. Dermatol. 122, 342\u2013348 (2004).","journal-title":"J. Invest. Dermatol."},{"key":"35657_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng1054","volume":"33","author":"PM Pollock","year":"2003","unstructured":"Pollock, P. M. et al. High frequency of BRAF mutations in nevi. Nat. Genet. 33, 19\u201320 (2003).","journal-title":"Nat. Genet."},{"key":"35657_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/sj.jid.5700490","volume":"127","author":"J Bauer","year":"2007","unstructured":"Bauer, J., Curtin, J. A., Pinkel, D. & Bastian, B. C. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J. Invest. Dermatol. 127, 179\u2013182 (2007).","journal-title":"J. Invest. Dermatol."},{"key":"35657_CR6","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1056\/NEJMra062285","volume":"355","author":"WJ Mooi","year":"2006","unstructured":"Mooi, W. J. & Peeper, D. S. Oncogene-induced cell senescence \u2014 halting on the road to cancer. N. Engl. J. Med. 355, 1037\u20131046 (2006).","journal-title":"N. Engl. J. Med."},{"key":"35657_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/sj.bjc.6603283","volume":"95","author":"VC Gray-Schopfer","year":"2006","unstructured":"Gray-Schopfer, V. C. et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 95, 496\u2013505 (2006).","journal-title":"Br. J. Cancer"},{"key":"35657_CR8","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nature03890","volume":"436","author":"C Michaloglou","year":"2005","unstructured":"Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720\u2013724 (2005).","journal-title":"Nature"},{"key":"35657_CR9","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1371\/journal.pbio.0060301","volume":"6","author":"J-P Copp\u00e9","year":"2008","unstructured":"Copp\u00e9, J.-P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, e301 (2008).","journal-title":"PLoS Biol."},{"key":"35657_CR10","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.tcb.2018.02.001","volume":"28","author":"A Hernandez-Segura","year":"2018","unstructured":"Hernandez-Segura, A., Nehme, J. & Demaria, M. Hallmarks of cellular senescence. Trends Cell Biol. 28, 436\u2013453 (2018).","journal-title":"Trends Cell Biol."},{"key":"35657_CR11","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1016\/j.jmb.2019.05.036","volume":"431","author":"A Soto-Gamez","year":"2019","unstructured":"Soto-Gamez, A., Quax, W. J. & Demaria, M. Regulation of survival networks in senescent cells: from mechanisms to interventions. J. Mol. Biol. 431, 2629\u20132643 (2019).","journal-title":"J. Mol. Biol."},{"key":"35657_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12979-020-00187-9","volume":"17","author":"A Kale","year":"2020","unstructured":"Kale, A. et al. Role of immune cells in the removal of deleterious senescent cells. Immun. Ageing 17, 1\u20139 (2020).","journal-title":"Immun. Ageing"},{"key":"35657_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.tcb.2020.07.002","volume":"30","author":"M Borghesan","year":"2020","unstructured":"Borghesan, M., Hoogaars, W. M. H., Varela-Eirin, M., Talma, N. & Demaria, M. A senescence-centric view of aging: implications for longevity and disease. Trends Cell Biol. 30, 777\u2013791 (2020).","journal-title":"Trends Cell Biol."},{"key":"35657_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms11190","volume":"7","author":"R Yosef","year":"2016","unstructured":"Yosef, R. et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun. 7, 1\u201311 (2016).","journal-title":"Nat. Commun."},{"key":"35657_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nm.4010","volume":"22","author":"J Chang","year":"2016","unstructured":"Chang, J. et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78\u201383 (2016).","journal-title":"Nat. Med."},{"key":"35657_CR16","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1016\/j.cub.2017.07.033","volume":"27","author":"A Hernandez-Segura","year":"2017","unstructured":"Hernandez-Segura, A. et al. Unmasking transcriptional heterogeneity in senescent cells. Curr. Biol. 27, 2652\u20132660.e4 (2017).","journal-title":"Curr. Biol."},{"key":"35657_CR17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/acel.12445","volume":"15","author":"Y Zhu","year":"2016","unstructured":"Zhu, Y. et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 15, 428\u2013435 (2016).","journal-title":"Aging Cell"},{"key":"35657_CR18","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.cmet.2019.01.021","volume":"29","author":"PJ Thompson","year":"2019","unstructured":"Thompson, P. J. et al. Targeted elimination of senescent beta cells prevents type 1 diabetes. Cell Metab. 29, 1045\u20131060.e10 (2019).","journal-title":"Cell Metab."},{"key":"35657_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18632\/aging.101202","volume":"9","author":"Y Zhu","year":"2017","unstructured":"Zhu, Y. et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging 9, 1\u20139 (2017).","journal-title":"Aging"},{"key":"35657_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.54954","volume":"9","author":"S Arai","year":"2020","unstructured":"Arai, S. et al. March5 mediates noxa-dependent mcl1 degradation driven by kinase inhibitors and integrated stress response activation. Elife 9, 1\u201324 (2020).","journal-title":"Elife"},{"key":"35657_CR21","doi-asserted-by":"crossref","unstructured":"Shahbandi, A. et al. BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer. Cell Death Differ. 27, 3097\u20133116 (2020).","DOI":"10.1038\/s41418-020-0564-6"},{"key":"35657_CR22","doi-asserted-by":"crossref","unstructured":"Leverson, J. D. et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis. 6, e1590 (2015).","DOI":"10.1038\/cddis.2014.561"},{"key":"35657_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-018-3302-0","volume":"11","author":"BSX Lian","year":"2018","unstructured":"Lian, B. S. X. et al. Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines. BMC Res. Notes 11, 197 (2018).","journal-title":"BMC Res. Notes"},{"key":"35657_CR24","doi-asserted-by":"crossref","unstructured":"Mukherjee, N. et al. MCL1 inhibitors S63845\/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 11, 443 (2020).","DOI":"10.1038\/s41419-020-2646-2"},{"key":"35657_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-019-1568-3","volume":"10","author":"EF Lee","year":"2019","unstructured":"Lee, E. F. et al. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis. 10, 1\u201314 (2019).","journal-title":"Cell Death Dis."},{"key":"35657_CR26","doi-asserted-by":"crossref","unstructured":"Wang, B. et al. The Bcl-2\/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells. Mol. Cancer 13, 98 (2014).","DOI":"10.1186\/1476-4598-13-98"},{"key":"35657_CR27","doi-asserted-by":"publisher","first-page":"369ra175","DOI":"10.1126\/scitranslmed.aae0348","volume":"8","author":"GR Anderson","year":"2016","unstructured":"Anderson, G. R. et al. PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. Sci. Transl. Med. 8, 369ra175 (2016).","journal-title":"Sci. Transl. Med."},{"key":"35657_CR28","doi-asserted-by":"publisher","first-page":"10853","DOI":"10.1073\/pnas.0804821105","volume":"105","author":"JR Mills","year":"2008","unstructured":"Mills, J. R. et al. mTORC1 promotes survival through translational control of Mcl-1. Proc. Natl Acad. Sci. USA 105, 10853\u201310858 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"35657_CR29","doi-asserted-by":"publisher","first-page":"E4036","DOI":"10.1073\/pnas.1512118112","volume":"112","author":"N Sekiyama","year":"2015","unstructured":"Sekiyama, N. et al. Molecular mechanism of the dual activity of 4EGI-1: Dissociating eIF4G from eIF4E but stabilizing the binding of unphosphorylated 4E-BP1. Proc. Natl Acad. Sci. 112, E4036\u2013E4045 (2015).","journal-title":"Proc. Natl Acad. Sci."},{"key":"35657_CR30","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1182\/blood-2010-05-285726","volume":"116","author":"B Hoang","year":"2010","unstructured":"Hoang, B. et al. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 116, 4560\u20134568 (2010).","journal-title":"Blood"},{"key":"35657_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy, A. et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538, 477\u2013482 (2016).","journal-title":"Nature"},{"key":"35657_CR32","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/ng.356","volume":"41","author":"D Dankort","year":"2009","unstructured":"Dankort, D. et al. BrafV600E cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544\u2013552 (2009).","journal-title":"Nat. Genet."},{"key":"35657_CR33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ccr.2009.02.022","volume":"15","author":"N Dhomen","year":"2009","unstructured":"Dhomen, N. et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15, 294\u2013303 (2009).","journal-title":"Cancer Cell"},{"key":"35657_CR34","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1158\/2159-8290.CD-12-0313","volume":"3","author":"O Maertens","year":"2013","unstructured":"Maertens, O. et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 3, 339\u2013349 (2013).","journal-title":"Cancer Discov."},{"key":"35657_CR35","doi-asserted-by":"publisher","first-page":"11493","DOI":"10.1158\/0008-5472.CAN-05-2211","volume":"65","author":"K Mercer","year":"2005","unstructured":"Mercer, K. et al. Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res. 65, 11493\u201311500 (2005).","journal-title":"Cancer Res."},{"key":"35657_CR36","doi-asserted-by":"crossref","unstructured":"Trucco, L. D. et al. Ultraviolet radiation\u2013induced DNA damage is prognostic for outcome in melanoma. Nat. Med. 25, 221\u2013224 (2019).","DOI":"10.1038\/s41591-018-0265-6"},{"key":"35657_CR37","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/nature13298","volume":"511","author":"A Viros","year":"2014","unstructured":"Viros, A. et al. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. Nature 511, 478\u2013482 (2014).","journal-title":"Nature"},{"key":"35657_CR38","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jid.2020.05.085","volume":"141","author":"LD Trucco","year":"2021","unstructured":"Trucco, L. D. et al. Map3k1 loss cooperates with BrafV600E to drive melanomagenesis. J. Invest. Dermatol. 141, 221\u2013225.e6 (2021).","journal-title":"J. Invest. Dermatol."},{"key":"35657_CR39","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1158\/2159-8290.CD-15-0196","volume":"5","author":"AS McNeal","year":"2015","unstructured":"McNeal, A. S. et al. CDKN2B loss promotes progression from benign melanocytic nevus to melanoma. Cancer Discov. 5, 1072\u20131085 (2015).","journal-title":"Cancer Discov."},{"key":"35657_CR40","doi-asserted-by":"crossref","unstructured":"Victorelli, S. et al. Senescent human melanocytes drive skin ageing via paracrine telomere dysfunction. EMBO J. 38, e101982 (2019).","DOI":"10.15252\/embj.2019101982"},{"key":"35657_CR41","doi-asserted-by":"publisher","first-page":"46801","DOI":"10.18632\/oncotarget.8695","volume":"8","author":"N Mukherjee","year":"2017","unstructured":"Mukherjee, N. et al. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget 8, 46801 (2017).","journal-title":"Oncotarget"},{"key":"35657_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12082182","volume":"12","author":"N Mukherjee","year":"2020","unstructured":"Mukherjee, N. et al. Simultaneously inhibiting BCL2 and MCL1 is a therapeutic option for patients with advanced melanoma. Cancers (Basel) 12, 1\u201316 (2020).","journal-title":"Cancers (Basel)"},{"key":"35657_CR43","first-page":"1","volume":"2","author":"DA Luedtke","year":"2017","unstructured":"Luedtke, D. A. et al. Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduct. Target. Ther. 2, 1\u20139 (2017).","journal-title":"Signal Transduct. Target. Ther."},{"key":"35657_CR44","doi-asserted-by":"publisher","first-page":"E1288","DOI":"10.1073\/pnas.1411848112","volume":"112","author":"AC Faber","year":"2015","unstructured":"Faber, A. C. et al. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc. Natl Acad. Sci. USA 112, E1288\u2013E1296 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"35657_CR45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","volume":"7","author":"M Demaria","year":"2017","unstructured":"Demaria, M. et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 7, 165\u2013176 (2017).","journal-title":"Cancer Discov."},{"key":"35657_CR46","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2008-02-137141","volume":"112","author":"DT Teachey","year":"2008","unstructured":"Teachey, D. T. et al. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 112, 2020\u20132023 (2008).","journal-title":"Blood"},{"key":"35657_CR47","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1111\/j.1349-7006.2009.01315.x","volume":"100","author":"T Matsuzaki","year":"2009","unstructured":"Matsuzaki, T. et al. Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci. 100, 2402\u20132410 (2009).","journal-title":"Cancer Sci."},{"key":"35657_CR48","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1097\/JTO.0b013e31820e1a25","volume":"6","author":"MA Hoda","year":"2011","unstructured":"Hoda, M. A. et al. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy. J. Thorac. Oncol. 6, 852\u2013863 (2011).","journal-title":"J. Thorac. Oncol."},{"key":"35657_CR49","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-018-0543-y","volume":"562","author":"TJ Bussian","year":"2018","unstructured":"Bussian, T. J. et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature 562, 578\u2013582 (2018).","journal-title":"Nature"},{"key":"35657_CR50","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1126\/science.aaf6659","volume":"354","author":"BG Childs","year":"2016","unstructured":"Childs, B. G. et al. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science 354, 472\u2013477 (2016).","journal-title":"Science"},{"key":"35657_CR51","doi-asserted-by":"crossref","unstructured":"Van Der Feen, D. E. et al. Cellular senescence impairs the reversibility of pulmonary arterial hypertension. Sci. Transl. Med. 12, eaaw4974 (2020).","DOI":"10.1126\/scitranslmed.aaw4974"},{"key":"35657_CR52","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421\u20133428 (2008).","journal-title":"Cancer Res."},{"key":"35657_CR53","doi-asserted-by":"crossref","unstructured":"Natale, C. A. et al. Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade. Elife 7, e31770 (2018).","DOI":"10.7554\/eLife.31770"},{"key":"35657_CR54","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1126\/sciadv.abn4007","volume":"8","author":"M Doepner","year":"2022","unstructured":"Doepner, M. et al. Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling. Sci. Adv. 8, 4007 (2022).","journal-title":"Sci. Adv."},{"key":"35657_CR55","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/exd.12594","volume":"24","author":"PC Billings","year":"2015","unstructured":"Billings, P. C., Sanzari, J. K., Kennedy, A. R., Cengel, K. A. & Seykora, J. T. Comparative analysis of colorimetric staining in skin using open-source software. Exp. Dermatol. 24, 157\u2013159 (2015).","journal-title":"Exp. Dermatol."},{"key":"35657_CR56","doi-asserted-by":"crossref","unstructured":"Panda, A., Martindale, J. & Gorospe, M. Polysome fractionation to analyze mRNA distribution profiles. Bio Protoc 7, e2126 (2017).","DOI":"10.21769\/BioProtoc.2126"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35657-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35657-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35657-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T14:03:33Z","timestamp":1671804213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35657-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["35657"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-35657-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"assertion":[{"value":"11 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.D. is founder, shareholder, and advisor for Cleara Biotech and an advisor for Oisin Biotechnologies. Neither Cleara Biotech nor Oisin Biotechnologies were involved in the study. The remaining authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7923"}}